Shanghai Allist Pharmaceuticals

Historical price data

Shanghai Allist Pharmaceuticals, founded in 2004, is a publicly traded biopharmaceutical innovator with a mission to leverage technology for improving patient lives. The company has successfully transitioned from a research organization to an integrated enterprise with a focus on kinase inhibitors for oncology and drugs for metabolic diseases, culminating in a high-profile IPO on the Shanghai STAR Market. Its strategy centers on advancing a deep clinical pipeline, capitalizing on China's supportive innovation policies, and pursuing global partnerships to maximize the value of its novel therapeutics.

A proprietary, integrated platform for small-molecule drug discovery with core expertise in structure-based design and optimization of kinase inhibitors, enabling efficient progression from target identification to clinical candidate selection.

Allist competes in the crowded but high-growth Chinese biotech sector, directly challenging other c-Met inhibitors and novel oncology therapies. Its differentiation lies in its integrated R&D platform and late-stage asset, but it must prove its commercial execution capabilities against both multinational and domestic rivals.